Van Lanschot Kempen N.V., a wealth manager operating under the Van Lanschot, Evi and Kempen brand names, is active in Private Banking, Asset Management and Merchant Banking, with the aim of preserving and creating wealth for its clients. Van Lanschot Kempen N.V., listed at Euronext Amsterdam, is the Netherlands' oldest independent financial services company with a history dating back to 1737.

Employees

2,072

Sector

Investment Management & Fund Operators

Calendar

02-26 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
12/02/26	49.05 €	+0.31%	72,243
11/02/26	48.90 €	-5.23%	219,943
10/02/26	51.60 €	+0.19%	38,000
09/02/26	51.50 €	+1.38%	55,462
06/02/26	50.80 €	+0.59%	45,319

Real-time Euronext Amsterdam

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

49.05EUR

Average target price

56.17EUR

Spread / Average Target

+14.51%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Amsterdam Other stock markets 16:55:00 12/02/2026 GMT			After hours 20:59:56
49.05 ^EUR	+0.31%		49.00	-0.10%

02-02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
01-29	Belgium's Agomab Therapeutics seeks up to $828.5 million valuation in US IPO	RE

Capitalization	2.08B 2.47B 1.9B 1.81B 3.36B 223B 3.48B 22.03B 8.76B 108B 9.25B 9.06B 376B	P/E ratio 2025 *	15.2x	P/E ratio 2026 *	14.2x
Enterprise value	2.08B 2.47B 1.9B 1.81B 3.36B 223B 3.48B 22.03B 8.76B 108B 9.25B 9.06B 376B	EV / Sales 2025 *	2.79x	EV / Sales 2026 *	2.66x
Free-Float	64.49%	Yield 2025 *	6.5%	Yield 2026 *	6.87%

02-02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
01-29	Belgium's Agomab Therapeutics seeks up to $828.5 million valuation in US IPO	RE
01-29	Belgium's Agomab Therapeutics seeks up to $828.5 million valuation in US IPO	RE
01-20	Catena Plans Directed Share Issue of 6 Million Shares	FW
01-16	Agomab Therapeutics files for US IPO - SEC filing	RE
01-07	KBC Group, Van Lanschot Kempen to Launch Specialist Equities JV	MT
01-06	KBC Securities, Van Lanschot Kempen Investment Banking announce JV in equities	RE
11-27	STOXX 600 ends steady after multiple-session rally; Puma, Allfunds jump on takeover buzz	RE
11-07	Aixtron Shares Retreat After Strong Gains Despite Positive Weekly Performance	DP
11-03	Aegon appoints new board chairman
27/10/25	Earnings calendar for October 27-31: Apple, Microsoft, Amazon, and others report
02/10/25	Hansa Biopharma to Raise $60 Million via Directed Share Issue	MT
03/09/25	Bioarctic's Two Major Shareholders Plan to Sell 2 Million Shares	FW

02-02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
11-07	Aixtron Shares Retreat After Strong Gains Despite Positive Weekly Performance	DP

Van Lanschot Kempen N.V Share Price

Equities

VLK

NL0000302636

Investment Management & Fund Operators

Valuation: Van Lanschot Kempen N.V

Chart: Van Lanschot Kempen N.V

Latest news: Van Lanschot Kempen N.V

Last Transcript: Van Lanschot Kempen N.V

Analysts' recommendations: Van Lanschot Kempen N.V

Press Releases: Van Lanschot Kempen N.V

News in other languages: Van Lanschot Kempen N.V

Quotes and Performance

Course Extremes

Managers and Directors: Van Lanschot Kempen N.V

Wealth Management

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-28	Van Lanschot Kempen N : secures fiduciary management mandate for Holcim Group pension plans	PU
01-20	Van Lanschot Kempen N : Stichting Pensioenfonds voor de Woningcorporaties selecteert Van Lanschot Kempen als fiduciair manager	PU
01-20	Van Lanschot Kempen N : Stichting Pensioenfonds voor de Woningcorporaties selects Van Lanschot Kempen as fiduciary manager	PU
12-16	Van Lanschot Kempen N : Maarten Edixhoven herbenoemd als voorzitter Raad van Bestuur Van Lanschot Kempen	PU
12-15	Van Lanschot Kempen N : Maarten Edixhoven reappointed as Chair of the Management Board of Van Lanschot Kempen	PU

01-29	Succesvolle introductie van open-end private-equityfonds gericht op secondaries: ruim € 150 miljoen ingetekend in lanceerperiode
01-28	Van Lanschot Kempen N : UK wint fiduciair mandaat voor pensioenregelingen van Holcim Groep
01-28	Van Lanschot Kempen UK aan de slag met pensioenen Holcim Groep
01-20	Stichting Pensioenfonds voor de Woningcorporaties kiest voor Van Lanschot
01-20	Van Lanschot Kempen N : Stichting Pensioenfonds voor de Woningcorporaties selecteert Van Lanschot Kempen als fiduciair manager

1 day	+0.31%
1 week	-3.63%
Current month	-4.01%
1 month	-8.66%
3 months	-2.68%
6 months	-16.30%
Current year	-7.28%

1 week	48.5	52.2
1 month	48.5	53.6
Current year	48.5	55.1
1 year	38	59.8
3 years	23.8	59.8
5 years	18.56	59.8
10 years	18.56	59.8

Manager	Title	Age	Since
Maarten Edixhoven CEO	Chief Executive Officer	55	30/09/2021
Jeroen Kroes DFI	Director of Finance/CFO	53	31/08/2022
Arjan J. Huisman COO	Chief Operating Officer	55	05/05/2010

Director	Title	Age	Since
Maarten H. Muller BRD	Director/Board Member	72	30/05/2018
Frans Blom CHM	Chairman	64	27/05/2020
Karin T. V. Bergstein BRD	Director/Board Member	59	27/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VAN LANSCHOT KEMPEN N.V	+0.31%	-3.63%	+1.34%	+77.40%	2.46B
BROOKFIELD WEALTH SOLUTIONS LTD.	+1.69%	+7.36%	+22.27%	+94.36%	14.4B
ST. JAMES'S PLACE PLC	0.00%	-17.24%	+12.35%	+1.37%	8.9B
SEI INVESTMENTS COMPANY	-3.55%	-8.39%	-5.75%	+22.63%	9.8B
STEPSTONE GROUP INC.	-4.60%	-4.39%	-5.45%	+95.34%	4.75B
L1 GROUP LIMITED	-3.20%	0.00%	-	-	2.28B
MAASE INC.	0.00%	+4.62%	-	-	2.17B
INSIGNIA FINANCIAL LTD.	0.00%	-0.65%	+0.22%	+33.91%	2.2B
UTI ASSET MANAGEMENT COMPANY LIMITED	-1.96%	+1.44%	+7.90%	+54.41%	1.56B
P10, INC.	-19.66%	-13.79%	-34.16%	-24.98%	1.16B
Average	-3.21%	-2.59%	-0.16%	+44.31%	4.97B
Weighted average by Cap.	-1.50%	-4.44%	+7.18%	+52.32%

	2025 *	2026 *
Net sales	745M 884M 680M 649M 1.2B 80.06B 1.25B 7.89B 3.14B 38.57B 3.31B 3.25B 135B	780M 926M 712M 680M 1.26B 83.87B 1.31B 8.27B 3.29B 40.41B 3.47B 3.4B 141B
Net income	138M 163M 126M 120M 222M 14.79B 230M 1.46B 580M 7.12B 612M 600M 24.88B	146M 173M 133M 127M 236M 15.7B 244M 1.55B 615M 7.56B 650M 636M 26.41B
Net Debt	-	-